MWNA
CASC

Marshall Wace North America’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Marshall Wace North America’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-13,443
Closed -$54K – 1779
2017
Q3 		$54K Buy
+13,443
New +$51.4K ﹤0.01% 1206

Other funds holding CASC

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
SH
Sandia Holdings Greenwich, Connecticut $213M AUM 29.35% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Marshall Wace North America's CASC Position: Q4 2017 in Review

Marshall Wace North America sold out of Cascadian Therapeutics, Inc. (CASC) in Q4 2017, closing a stake of 13,443 shares — an estimated $54K sold.

Marshall Wace North America first reported a position in CASC in Q3 2017 and held it in 1 quarter. The position peaked at $54K in Q3 2017. 91 funds tracked by Wall St. Rank hold CASC as of Q4 2017.

  • Marshall Wace North America reported no remaining Cascadian Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Marshall Wace North America sold 13,443 Cascadian Therapeutics, Inc. shares in Q4 2017, an estimated $54K.
  • Marshall Wace North America first reported a position in Cascadian Therapeutics, Inc. in Q3 2017 and held it in 1 quarter.
  • Marshall Wace North America's Cascadian Therapeutics, Inc. position peaked at $54K in Q3 2017.
  • 91 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q4 2017.

Based on Marshall Wace North America's 13F filing for Q4 2017, filed 14 Feb 2018.